Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study

Stattin, P; Bylund, A; Rinaldi, S; Biessy, C; Dechaud, H; Stenman, Uh; Egevad, L; Riboli, E; Hallmans, G; Kaaks, R

doi:10.1093/jnci/92.23.1910

CINECA IRIS Institutional Research Information System

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

Background: Recent studies have suggested that men with elevated plasma levels of insulin-like growth factor-I (IGF-I) may have an increased risk of prostate cancer. Furthermore, IGF-binding proteins (IGFBPs) and insulin can modulate the activity of IGF-I, In this study, we sought to determine the role of IGF-I as well as IGFBPs-1, -2, and -3 and insulin as possible etiologic factors for prostate cancer. Methods: We conducted a nested case-control study within the Northern Sweden Health and Disease Cohort Study. We measured levels of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, and insulin in plasma samples from 149 men who had a diagnosis of prostate cancer between I month and 10 Sears after blood collection and among 298 control men. All statistical tests are two-sided. Results: Case subjects had statistically significantly higher mean levels of IGF-I than control subjects (229 ng/mL; 95% confidence interval [CT] = 218-240 ng/mL] versus 214 ng/mL [95% CI = 208-221 ng/mL]; P = .02) and IGFBP-3 (2611 ng/mL [95% CI = 2518-2704 ng/mL] versus 2498 ng/mL [95% CI = 2437-2560 ng/mL]; P = .04). Conditional logistic regression analyses showed increases in prostate cancer risk with rising levels of IGF-I (P-for trend = .02) and IGFBP-3 (P-for trend = .03). In case subjects younger than 59 years at the time of blood collection, the risk associated with increased IGF-I was higher (P-for trend = .01), whereas the risk associated with increased IGFBP-3 was lower (P-for trend = .44) than the corresponding risks in the full cohort. Prostate cancer risk was not associated with levels of IGFBP-1, IGFBP-2, or insulin. Conclusions: Prostate cancer risk is increased in men with elevated plasma IGF-I, This association was particularly strong in younger men in this study, suggesting that circulating IGF-I mag be specifically involved in the early pathogenesis of prostate cancer.

Titolo:	Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study
Autori:	Stattin P Bylund A Rinaldi S Biessy C Dechaud H Stenman UH Egevad L RIBOLI, Elio Hallmans G Kaaks R mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2000
Rivista:	JOURNAL OF THE NATIONAL CANCER INSTITUTE
Abstract:	Background: Recent studies have suggested that men with elevated plasma levels of insulin-like growth factor-I (IGF-I) may have an increased risk of prostate cancer. Furthermore, IGF-binding proteins (IGFBPs) and insulin can modulate the activity of IGF-I, In this study, we sought to determine the role of IGF-I as well as IGFBPs-1, -2, and -3 and insulin as possible etiologic factors for prostate cancer. Methods: We conducted a nested case-control study within the Northern Sweden Health and Disease Cohort Study. We measured levels of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, and insulin in plasma samples from 149 men who had a diagnosis of prostate cancer between I month and 10 Sears after blood collection and among 298 control men. All statistical tests are two-sided. Results: Case subjects had statistically significantly higher mean levels of IGF-I than control subjects (229 ng/mL; 95% confidence interval [CT] = 218-240 ng/mL] versus 214 ng/mL [95% CI = 208-221 ng/mL]; P = .02) and IGFBP-3 (2611 ng/mL [95% CI = 2518-2704 ng/mL] versus 2498 ng/mL [95% CI = 2437-2560 ng/mL]; P = .04). Conditional logistic regression analyses showed increases in prostate cancer risk with rising levels of IGF-I (P-for trend = .02) and IGFBP-3 (P-for trend = .03). In case subjects younger than 59 years at the time of blood collection, the risk associated with increased IGF-I was higher (P-for trend = .01), whereas the risk associated with increased IGFBP-3 was lower (P-for trend = .44) than the corresponding risks in the full cohort. Prostate cancer risk was not associated with levels of IGFBP-1, IGFBP-2, or insulin. Conclusions: Prostate cancer risk is increased in men with elevated plasma IGF-I, This association was particularly strong in younger men in this study, suggesting that circulating IGF-I mag be specifically involved in the early pathogenesis of prostate cancer.
Handle:	http://hdl.handle.net/11699/9709
Appare nelle tipologie:	1.1 Articolo in rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11699/9709

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.